New insights into lipid metabolism and prostate cancer (Review)

Prostate cancer (PCa) is the most common malignant tumor of the male urological system and poses a severe threat to the survival of middle-aged and elderly males worldwide. The development and progression of PCa are affected by a variety of biological processes, including proliferation, apoptosis, migration, invasion and the maintenance of membrane homeostasis of PCa cells. The present review summarizes recent research advances in lipid (fatty acid, cholesterol and phospholipid) metabolic pathways in PCa. In the first section, the metabolism of fatty acids is highlighted, from formation to catabolism and associated proteins. Subsequently, the role of cholesterol in the pathogenesis and evolution of PCa is described in detail. Finally, the different types of phospholipids and their association with PCa progression is also discussed. In addition to the impact of key proteins of lipid metabolism on PCa growth, metastasis and drug resistance, the present review also summarizes the clinical value of fatty acids, cholesterol and phospholipids, as diagnostic and prognostic indicators and therapeutic targets in PCa.

[1]  L. Horvath,et al.  Targeting lipid metabolism in metastatic prostate cancer , 2023, Therapeutic advances in medical oncology.

[2]  Zhaoqi Zhang,et al.  FABP5 controls macrophage alternative activation and allergic asthma by selectively programming long-chain unsaturated fatty acid metabolism. , 2022, Cell reports.

[3]  M. Stockler,et al.  Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin , 2022, Cancers.

[4]  M. Ediriweera Use of cholesterol metabolism for anti-cancer strategies. , 2022, Drug discovery today.

[5]  F. Saad,et al.  Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up , 2022, Cancers.

[6]  Wei Xue,et al.  Squalene epoxidase metabolic dependency is a targetable vulnerability in castration-resistant prostate cancer. , 2022, Cancer research.

[7]  A. Patnaik,et al.  Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer , 2022, bioRxiv.

[8]  Hui Zhang,et al.  ELOVL2 restrains cell proliferation, migration, and invasion of prostate cancer via regulation of the tumor suppressor INPP4B. , 2022, Cellular signalling.

[9]  J. Carles,et al.  Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER , 2022, European journal of cancer.

[10]  F. Brimo,et al.  Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients , 2022, Oncogene.

[11]  N. Pavlova,et al.  The hallmarks of cancer metabolism: Still emerging. , 2022, Cell metabolism.

[12]  R. Schwabe,et al.  Inhibition of carnitine palmitoyl-transferase 1A in hepatic stellate cells protects against fibrosis. , 2022, Journal of hepatology.

[13]  J. Pardo,et al.  Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer , 2022, Nutrients.

[14]  Jordan F Hastings,et al.  Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover , 2022, Cancer & Metabolism.

[15]  Stephen L. Pinkosky,et al.  Lipogenesis inhibitors: therapeutic opportunities and challenges , 2022, Nature Reviews Drug Discovery.

[16]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[17]  D. Hanahan Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[18]  A. Ziegler,et al.  A hormone complex of FABP4 and nucleoside kinases regulates islet function , 2021, Nature.

[19]  Hongqiang Cheng,et al.  Oxidative stress-induced FABP5 S-glutathionylation protects against acute lung injury by suppressing inflammation in macrophages , 2021, Nature Communications.

[20]  C. Cordon-Cardo,et al.  MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway. , 2021, Cancer letters.

[21]  Guan-Jhong Huang,et al.  Cell suspension culture extract of Eriobotrya japonica attenuates growth and induces apoptosis in prostate cancer cells via targeting SREBP-1/FASN-driven metabolism and AR. , 2021, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[22]  M. Cox,et al.  Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer , 2021, Pharmaceutics.

[23]  Yi Sun,et al.  ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer , 2021, Cancers.

[24]  R. Oliart-Ros,et al.  Inhibition of Stearoyl-CoA Desaturase by Sterculic Oil Reduces Proliferation and Induces Apoptosis in Prostate Cancer Cell Lines , 2021, Nutrition and cancer.

[25]  I. Csizmadi,et al.  Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer , 2021, The Journal of urology.

[26]  F. Bruyère,et al.  Lipophagy and prostate cancer: association with disease aggressiveness and proximity to periprostatic adipose tissue , 2021, The Journal of pathology.

[27]  V. Zuber,et al.  The relationship between Lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study. , 2021, medRxiv.

[28]  B. Staels,et al.  PPAR control of metabolism and cardiovascular functions , 2021, Nature Reviews Cardiology.

[29]  R. Gillies,et al.  Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer , 2021, Cancer Research.

[30]  M. Loda,et al.  ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer , 2021, Cancer Research.

[31]  Yanqing Wang,et al.  HOXD13 suppresses prostate cancer metastasis and BMP4‐induced epithelial‐mesenchymal transition by inhibiting SMAD1 , 2021, International journal of cancer.

[32]  Yuan Liu,et al.  Knockdown of sterol O-acyltransferase 1 (SOAT1) suppresses SCD1-mediated lipogenesis and cancer procession in prostate cancer. , 2021, Prostaglandins & other lipid mediators.

[33]  R. Godbout,et al.  An Amplified Fatty Acid-Binding Protein Gene Cluster in Prostate Cancer: Emerging Roles in Lipid Metabolism and Metastasis , 2020, Cancers.

[34]  C. Thaxton,et al.  Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol‐dependent manner , 2020, Journal of extracellular vesicles.

[35]  A. Scott,et al.  Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. , 2020, Nuclear medicine and biology.

[36]  E. Lerma,et al.  LDL, HDL and endocrine-related cancer: from pathogenic mechanisms to therapies. , 2020, Seminars in cancer biology.

[37]  C. Thompson,et al.  Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis , 2020, Proceedings of the National Academy of Sciences.

[38]  J. Kench,et al.  Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition , 2020, Cancer Research.

[39]  Xianming Deng,et al.  Blocking PPARγ interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression , 2020, Proceedings of the National Academy of Sciences.

[40]  R. Godbout,et al.  The FABP12/PPARγ pathway promotes metastatic transformation by inducing epithelial‐to‐mesenchymal transition and lipid‐derived energy production in prostate cancer cells , 2020, Molecular oncology.

[41]  R. Mancini,et al.  Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition , 2020, Journal of experimental & clinical cancer research : CR.

[42]  M. Kaczocha,et al.  FABP5 as a novel molecular target in prostate cancer. , 2020, Drug discovery today.

[43]  W. Wahli,et al.  GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK. , 2020, Cell reports.

[44]  E. Sauter,et al.  SnapShot: FABP Functions , 2020, Cell.

[45]  B. Dai,et al.  Targeting CPT1B as a potential therapeutic strategy in castration‐resistant and enzalutamide‐resistant prostate cancer , 2020, The Prostate.

[46]  Giovanny Rodriguez Blanco,et al.  2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer , 2020, Nature Communications.

[47]  Hong-xia Li,et al.  GPR120 facilitates cholesterol efflux in macrophages through activation of AMPK signaling pathway , 2020, The FEBS journal.

[48]  Xiaoxuan Liu,et al.  Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[49]  A. Harraz,et al.  Evaluation of serum fatty acid binding protein-4 (FABP-4) as a novel biomarker to predict biopsy outcomes in prostate biopsy naïve patients , 2020, International Urology and Nephrology.

[50]  M. Loda,et al.  Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases , 2020, Oncogene.

[51]  J. Turkson,et al.  27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6–JAK–STAT3 Signaling in Prostate Cancer Cells , 2020, Molecular Cancer Research.

[52]  M. Gomaraschi Role of Lipoproteins in the Microenvironment of Hormone-Dependent Cancers , 2019, Trends in Endocrinology & Metabolism.

[53]  M. Kaczocha,et al.  FABP5 coordinates lipid signaling that promotes prostate cancer metastasis , 2019, Scientific Reports.

[54]  L. Trotman,et al.  Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth , 2019, The Prostate.

[55]  Bart W. J. Philips,et al.  A multitransmit external body array combined with a 1H and 31P endorectal coil to enable a multiparametric and multimetabolic MRI examination of the prostate at 7T , 2019, Medical physics.

[56]  G. Wang,et al.  Upregulation of Scavenger receptor B1 is required for steroidogenic and non-steroidogenic cholesterol metabolism in prostate cancer. , 2019, Cancer research.

[57]  Shan Gao,et al.  Cholesterol Induces Epithelial-to-Mesenchymal Transition of Prostate Cancer Cells by Suppressing Degradation of EGFR through APMAP. , 2019, Cancer research.

[58]  A. Scorilas,et al.  Molecular characterization, genomic structure and expression analysis of a gene (CATL1/CPT1C) encoding a third member of the human carnitine acyltransferase family. , 2019, Genomics.

[59]  V. Giri,et al.  Diet assessment among men undergoing genetic counseling and genetic testing for inherited prostate cancer: Exploring a teachable moment to support diet intervention , 2019, The Prostate.

[60]  M. D. De Velasco,et al.  HOXA10 expression profiling in prostate cancer , 2019, The Prostate.

[61]  K. Taari,et al.  Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study , 2019, Prostate cancer and prostatic diseases.

[62]  L. Fazli,et al.  Roles of the HOXA10 gene during castrate-resistant prostate cancer progression. , 2019, Endocrine-related cancer.

[63]  Elizabeth C. Randall,et al.  Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging , 2019, Molecular Cancer Research.

[64]  D. Sabatini,et al.  Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death , 2019, Nature.

[65]  D. Nomura,et al.  Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer , 2019, Science Translational Medicine.

[66]  P. Muti,et al.  Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. , 2019, Cell metabolism.

[67]  M. Loda,et al.  Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer , 2018, Proceedings of the National Academy of Sciences.

[68]  K. Gardner,et al.  CTBP1/CYP19A1/estradiol axis together with adipose tissue impacts over prostate cancer growth associated to metabolic syndrome , 2018, International journal of cancer.

[69]  A. Esnakula,et al.  Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men , 2018, The Prostate.

[70]  H. Stahlberg,et al.  Structural basis for regulation of human acetyl-CoA carboxylase , 2018, Nature.

[71]  Shuyan Liu,et al.  SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis. , 2018, Cancer letters.

[72]  S. Raimondo,et al.  Label-free quantitative proteomic profiling of colon cancer cells identifies acetyl-CoA carboxylase alpha as antitumor target of Citrus limon-derived nanovesicles. , 2018, Journal of proteomics.

[73]  F. Kraemer,et al.  SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux. , 2018, Annual review of physiology.

[74]  D. Ford,et al.  Phospholipid Remodeling and Cholesterol Availability Regulate Intestinal Stemness and Tumorigenesis. , 2018, Cell stem cell.

[75]  J. Clohessy,et al.  An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer , 2018, Nature Genetics.

[76]  I. Mills,et al.  Genetics of lipid metabolism in prostate cancer , 2018, Nature Genetics.

[77]  Kshitij Srivastava,et al.  Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence. , 2017, Cell metabolism.

[78]  M. Stockler,et al.  A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer , 2017, International Journal of Cancer.

[79]  K. Takayama,et al.  ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells , 2017, Cancer science.

[80]  S. S. Kanwar,et al.  Phosphatidylserine: A cancer cell targeting biomarker. , 2017, Seminars in cancer biology.

[81]  William A. Flavahan,et al.  Epigenetic plasticity and the hallmarks of cancer , 2017, Science.

[82]  H. Han,et al.  BNIP3 induction by hypoxia stimulates FASN-dependent free fatty acid production enhancing therapeutic potential of umbilical cord blood-derived human mesenchymal stem cells , 2017, Redox biology.

[83]  Jianmin Wang,et al.  Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer. , 2017, Cancer letters.

[84]  N. Azad,et al.  Anti‐Tumorigenic Potential of a Novel Orlistat‐AICAR Combination in Prostate Cancer Cells , 2017, Journal of cellular biochemistry.

[85]  V. Parra,et al.  Calcium Transport and Signaling in Mitochondria. , 2017, Comprehensive Physiology.

[86]  Y. Furuya,et al.  Simvastatin Up‐Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen‐Independent Human Prostate Cancer Cells , 2017, The Prostate.

[87]  S. Freedland,et al.  The current evidence on statin use and prostate cancer prevention: are we there yet? , 2017, Nature Reviews Urology.

[88]  Y. Zou,et al.  FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1 , 2016, Proceedings of the National Academy of Sciences.

[89]  Christian M. Metallo,et al.  ATP-Citrate Lyase Controls a Glucose-to-Acetate Metabolic Switch. , 2016, Cell reports.

[90]  Jennifer R. Rider,et al.  Cholesterol Metabolism and Prostate Cancer Lethality. , 2016, Cancer research.

[91]  B. Stockwell,et al.  Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis , 2016, Proceedings of the National Academy of Sciences.

[92]  J. Fernandez-Checa,et al.  Mitochondria, cholesterol and cancer cell metabolism , 2016, Clinical and Translational Medicine.

[93]  L. Arab,et al.  Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project , 2016, Prostate Cancer and Prostatic Diseases.

[94]  A. Rust,et al.  Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer , 2016, Proceedings of the National Academy of Sciences.

[95]  Navdeep S. Chandel,et al.  Fundamentals of cancer metabolism , 2016, Science Advances.

[96]  L. Butler,et al.  Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. , 2016, Endocrine-related cancer.

[97]  J. Locasale,et al.  The Warburg Effect: How Does it Benefit Cancer Cells? , 2016, Trends in biochemical sciences.

[98]  M. Golzio,et al.  Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity , 2016, Nature Communications.

[99]  Richard Ventura,et al.  Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression , 2015, EBioMedicine.

[100]  Saumyadipta Pyne,et al.  AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. , 2014, Cancer research.

[101]  D. Xiao,et al.  Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth. , 2014, Cancer letters.

[102]  S. Langley,et al.  Importance of HOX genes in normal prostate gland formation, prostate cancer development and its early detection , 2014, BJU international.

[103]  Zhi-ping Chen,et al.  A lincRNA-DYNLRB2-2/GPR119/GLP-1R/ABCA1-dependent signal transduction pathway is essential for the regulation of cholesterol homeostasis , 2014, Journal of Lipid Research.

[104]  Ji-Xin Cheng,et al.  Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. , 2014, Cell metabolism.

[105]  Xiangyan Li,et al.  Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling , 2014, Molecular Cancer Therapeutics.

[106]  T. Salo,et al.  The Fatty Acid Synthase Inhibitor Orlistat Reduces the Growth and Metastasis of Orthotopic Tongue Oral Squamous Cell Carcinomas , 2013, Molecular Cancer Therapeutics.

[107]  Jayantha B. Tennakoon,et al.  Androgens Regulate Prostate Cancer Cell Growth via an AMPK-PGC-1α-Mediated Metabolic Switch , 2013, Oncogene.

[108]  S. Freedland,et al.  The relationship between nutrition and prostate cancer: is more always better? , 2013, European urology.

[109]  Pier Paolo Pandolfi,et al.  Cancer metabolism: fatty acid oxidation in the limelight , 2013, Nature Reviews Cancer.

[110]  C. Magi-Galluzzi,et al.  Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. , 2013, Cancer research.

[111]  J. Krycer,et al.  A key regulator of cholesterol homoeostasis, SREBP-2, can be targeted in prostate cancer cells with natural products. , 2012, The Biochemical journal.

[112]  T. Wilt,et al.  Statin Use and Risk of Prostate Cancer in the Prospective Osteoporotic Fractures in Men (MrOS) Study , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[113]  L. Chung,et al.  Activation of Androgen Receptor, Lipogenesis, and Oxidative Stress Converged by SREBP-1 Is Responsible for Regulating Growth and Progression of Prostate Cancer Cells , 2011, Molecular Cancer Research.

[114]  G. Mills,et al.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.

[115]  S. Kridel,et al.  Polyunsaturated fatty acid metabolism in prostate cancer , 2011, Cancer and Metastasis Reviews.

[116]  S. Balk,et al.  Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. , 2011, Endocrine-related cancer.

[117]  M. Freeman,et al.  The complex interplay between cholesterol and prostate malignancy. , 2011, The Urologic clinics of North America.

[118]  Matej Oresic,et al.  Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. , 2011, Cancer research.

[119]  F. Hanisch,et al.  Lipid rafts: signaling and sorting platforms of cells and their roles in cancer , 2011, Expert review of proteomics.

[120]  R. Komoroski,et al.  31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia , 2011, Magnetic resonance in medicine.

[121]  Yuan Yuan Wang,et al.  Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. , 2011, Cancer research.

[122]  Chawnshang Chang,et al.  Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation , 2011, Molecules and cells.

[123]  Wendy A Wells,et al.  Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation , 2011, Molecular Cancer Therapeutics.

[124]  M. Thun,et al.  Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. , 2010, Cancer research.

[125]  K. Solomon,et al.  Prohibitin is a cholesterol‐sensitive regulator of cell cycle transit , 2010, Journal of cellular biochemistry.

[126]  M. Loda,et al.  Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[128]  S. Culine,et al.  Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice , 2010, Molecular Cancer Therapeutics.

[129]  G. Marceau,et al.  Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells , 2010, Oncogene.

[130]  C. Nelson,et al.  Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration‐resistant prostate cancer in a mouse xenograft model , 2010, The Prostate.

[131]  M. Gleave,et al.  Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance , 2010, The Prostate.

[132]  I. Thompson,et al.  Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[133]  Yusuke Nakamura,et al.  Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. , 2009, Cancer research.

[134]  M. Gleave,et al.  Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[135]  W. Hahn,et al.  Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. , 2009, Journal of the National Cancer Institute.

[136]  G. Schwartz,et al.  Hypercholesterolemia and prostate cancer: a hospital-based case–control study , 2008, Cancer Causes & Control.

[137]  J. Storch,et al.  The emerging functions and mechanisms of mammalian fatty acid-binding proteins. , 2008, Annual review of nutrition.

[138]  E. Rimm,et al.  Statin drugs and risk of advanced prostate cancer. , 2006, Journal of the National Cancer Institute.

[139]  Y. Liu,et al.  Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.

[140]  W. Welshons,et al.  Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer , 2006, Molecular and Cellular Endocrinology.

[141]  K. T. Patton,et al.  Decreased annexin I expression in prostatic adenocarcinoma and in high‐grade prostatic intraepithelial neoplasia , 2005, Histopathology.

[142]  M. Freeman,et al.  Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer , 2005, Trends in Endocrinology & Metabolism.

[143]  F. Ichas,et al.  Amplification of Fas-Mediated Apoptosis in Type II Cells via Microdomain Recruitment , 2005, Molecular and Cellular Biology.

[144]  J. Menéndez,et al.  Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[145]  Jayoung Kim,et al.  Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. , 2005, The Journal of clinical investigation.

[146]  P. Febbo,et al.  Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. , 2003, Molecular cancer research : MCR.

[147]  P. Rudland,et al.  High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity , 2003, Oncogene.

[148]  M. Freeman,et al.  Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. , 2002, Cancer research.

[149]  E. Ikonen,et al.  How cells handle cholesterol. , 2000, Science.

[150]  J. Hsuan,et al.  Epidermal growth factor receptor activation is localized within low-buoyant density, non-caveolar membrane domains. , 1999, The Biochemical journal.

[151]  P. Carroll,et al.  Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. , 1996, Cancer research.

[152]  J. Cutler,et al.  Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. , 1987, JAMA.

[153]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[154]  A. Jemal,et al.  Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. , 2019, European urology.

[155]  S. Freedland,et al.  Words of wisdom. Re: Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. , 2013, European urology.

[156]  C. Nelson,et al.  Androgen‐mediated cholesterol metabolism in LNCaP and PC‐3 cell lines is regulated through two different isoforms of acyl‐coenzyme A: Cholesterol Acyltransferase (ACAT) , 2008, The Prostate.

[157]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[158]  M. Freeman,et al.  Cholesterol and prostate cancer , 2004, Journal of cellular biochemistry.

[159]  H. Kolb,et al.  Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. , 1986, Biological chemistry Hoppe-Seyler.